Kaida BioPharma Launches Social Media Channels
September 18, 2024 10:00 ET
|
Kaida Biopharma
Company dedicated to providing a new hope for patients with treatment-resistant gynecological cancers Lead program, KAD101 for the treatment of ovarian cancer rapidly advancing towards Phase 1...
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
September 04, 2024 09:25 ET
|
Hepion Pharmaceuticals, Inc.
KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product...
Triyam Recognized on Inc. 5000 List for the Fourth Consecutive Year
August 15, 2024 09:00 ET
|
Access Information Management Shared Services, LLC
Company ranking leveled up 999 spots on this highlighted list of America’s Fastest-Growing Private Companies
Privia Health Reports Second Quarter 2024 Financial Results
August 08, 2024 06:00 ET
|
Privia Health Group, Inc.
Strong Execution Across All Business and Financial MetricsRaised Full-Year 2024 Guidance to Mid to High End for All Metrics ARLINGTON, Va., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Privia Health Group,...
United Community Banks, Inc. Announces Transfer of Listing of Common Stock and Depositary Shares to NYSE
July 26, 2024 07:30 ET
|
United Community Banks, Inc.
GREENVILLE, S.C., July 26, 2024 (GLOBE NEWSWIRE) -- United Community Banks, Inc. (NASDAQ: UCBI; UCBIO) (the “Company” or “United”) announced today that the Company will transfer the listing of its...
United Community Banks, Inc. Reports Second Quarter Results
July 24, 2024 07:45 ET
|
United Community Banks, Inc.
GREENVILLE, S.C., July 24, 2024 (GLOBE NEWSWIRE) -- United Community Banks, Inc. (NASDAQ: UCBI) (United) today announced that net income for the 2024 second quarter was $66.6 million and pre-tax,...
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
July 22, 2024 08:00 ET
|
Hepion Pharmaceuticals, Inc.
Pharma Two B Ltd. (“Pharma Two B”) has entered into a merger agreement with Hepion Pharmaceuticals, Inc. (“Hepion”) (Nasdaq: HEPA)Immediately upon completion of the merger, current Pharma Two B...
Privia Health to Report Second Quarter 2024 Results on Thursday, August 8
July 11, 2024 09:00 ET
|
Privia Health Group, Inc.
ARLINGTON, Va., July 11, 2024 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it plans to release financial results for its second quarter and six-month periods...
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease
July 09, 2024 20:00 ET
|
Io Therapeutics, Inc.
Io Therapeutics presented data on the potential of IRX4204 for treatment of aging-related neurodegeneration, Parkinson's disease, and Alzheimer's disease
GRI Bio Announces Closing of $4.0 Million Public Offering
June 28, 2024 16:05 ET
|
GRI Bio, Inc.
LA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...